Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

EBITDA Summary of Xeris Biopharma Holdings, Inc.

  • Xeris Biopharma Holdings, Inc.'s latest annual EBITDA in 2024 was -23.73 Million USD , up 65.76% from previous year.
  • Xeris Biopharma Holdings, Inc.'s latest quarterly EBITDA in 2024 FY was N/A , up 56.61% from previous quarter.
  • Xeris Biopharma Holdings, Inc. reported an annual EBITDA of -69.31 Million USD in 2023, down 0.0% from previous year.
  • Xeris Biopharma Holdings, Inc. reported an annual EBITDA of -113.66 Million USD in 2022, up 37.96% from previous year.
  • Xeris Biopharma Holdings, Inc. reported a quarterly EBITDA of N/A for 2024 FY, up 56.61% from previous quarter.
  • Xeris Biopharma Holdings, Inc. reported a quarterly EBITDA of -11.03 Million USD for 2024 Q3, down -151.63% from previous quarter.

Annual EBITDA Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual EBITDA of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year EBITDA EBITDA Growth
2024 -23.73 Million USD 65.76%
2023 -69.31 Million USD 0.0%
2022 -113.66 Million USD 37.96%
2021 -80.07 Million USD -42.22%
2020 -117.79 Million USD -39.58%
2019 -57.21 Million USD -119.27%
2018 -26.37 Million USD -100.75%
2017 -13.09 Million USD 0.0%

Peer EBITDA Comparison of Xeris Biopharma Holdings, Inc.

Name EBITDA EBITDA Difference
Arrowhead Pharmaceuticals, Inc. -175.67 Million USD 86.489%
Codexis, Inc. -49.28 Million USD 51.839%
Viridian Therapeutics, Inc. -234.56 Million USD 89.881%
Organovo Holdings, Inc. -14.8 Million USD -60.307%